Focus: Ichnos Glenmark Innovation is a biotech subsidiary of Glenmark Pharma focused on bispecific antibodies across cardiovascular, neurology, immunology, women's health, and respiratory indications. The company operates at mid-scale (51-200 employees) with a New York headquarters and early-stage pipeline programs.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Ichnos Glenmark Innovation to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver (30% of company revenue) but post-loss-of-exclusivity generic, facing ongoing price/volume erosion.
Help build intelligence for Ichnos Glenmark Innovation
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ichnos Glenmark Innovation's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue contributor at near-patent cliff; critical for near-term cash flow but faces imminent generic competition.
Peak-stage product with longest remaining patent life (2033 LOE); provides mid-term revenue stability and longest commercial runway.
Post-LOE generic with minimal revenue; represents legacy portfolio weight rather than growth opportunity.
Post-LOE generic with minimal revenue contribution; tactical respiratory asset with limited upside.
Post-LOE generic with negligible revenue; peripheral to core business strategy.
Post-LOE generic topical with minimal revenue; small revenue contributor to overall portfolio.
Post-LOE generic with minimal revenue; cardiovascular portfolio anchor but mature/declining.
Post-LOE generic topical corticosteroid with minimal revenue; peripheral dermatology asset.
74 discontinued, 101 duplicate formulations not shown
+1 more products with revenue data
Glenmark Pharma's biotech arm IGI unveils ISB 2301 to target solid tumors - scanx.trade
Glenmark Pharma's biotech arm IGI unveils ISB 2301 to target solid tumors scanx.trade
Glenmark's innovation arm develops new candidate for cancer treatment - BioSpectrum India
Glenmark's innovation arm develops new candidate for cancer treatment BioSpectrum India
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+102 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo